As indications for PARPis expand, and PARPis become incorporated into earlier lines of therapy, the issue of PARP inhibitor resistance becomes increasingly important and one that a clinician caring for patients with ovarian cancer will certainly have to face. Here, PARP1 is linked to ovarian cancer.